Paul E. Kalb, M.D., Author at Enhanced Scrutiny

About Paul E. Kalb, M.D.

This author has not written his bio yet.
But we are proud to say that Paul E. Kalb, M.D. contributed 3 entries already.

Entries by Paul E. Kalb, M.D.

16 02 '23

Where Caremark Meets Park: A New Era of Regulatory Compliance and Criminal Liability

February 16, 2023/in Best Practices, Caremark/by Paul E. Kalb, M.D.

In a recent post on PharmExec.com, Paul Kalb (a co-founder of Sidley’s Global Life Science practice) and Coleen Klasmeier (a former partner who co-led Sidley’s Food, Drug and Medical Device […]

04 11 '21

Increased Scrutiny Has Boards of Directors in the Hot Seat

November 4, 2021/in Best Practices, Caremark/by Paul E. Kalb, M.D.

Life is getting harder for boards of directors of public companies. Increased scrutiny of companies — particularly in heavily regulated industries — has led to greater risk of criminal and […]

08 10 '21

Boeing Case Highlights Risk For Health, Life Sciences Boards

October 8, 2021/in Best Practices, Caremark, Derivative Litigation/by Paul E. Kalb, M.D.

On Sept. 7, the Delaware Chancery Court allowed In re: The Boeing Co. Derivative Litigation to proceed, surviving a motion to dismiss.[1] The action alleges that directors breached their fiduciary […]

About Paul E. Kalb, M.D.

Entries by Paul E. Kalb, M.D.

SUBSCRIBE